Skip to main content
. Author manuscript; available in PMC: 2011 Jun 2.
Published in final edited form as: Bioconjug Chem. 2009 Jul 2;20(8):1650–1659. doi: 10.1021/bc900206g

Figure 1.

Figure 1

Comparison of G3 dendrimer conjugates as agonists at the human P2Y14 receptor. The capacities of UDPGA 2 (■) and the G3 dendrimer conjugates 5 (◆), 8 (○), and 9 (□) to inhibit forskolin (30 μM) stimulated cyclic AMP accumulation were quantified in P2Y14–HEK293 cells as described in Methods. Assays were carried out in triplicate, and all experiments were repeated at least three times. Data were pooled and normalized using forskolin-stimulated cyclic AMP accumulation as 100% and the phosphodiesterase inhibitor IBMX alone as 0%.